Since Solomon Ibn Gabirol left the world and Moses Ibn Ezra, Jehudah Halevi, and Abraham Ibn Ezra died, the well of poetry has dried up, inspiration has disappeared, and God’s spirit no longer manifests itself. None of their successors can compare with them. We backward ones, like beggars, gather the crumbs and refuse that have fallen from their table. We hasten day and night over the ways trod...

Cancer-induced bone diseases are often associated with increased bone resorption and pathological fractures. In recent years, osteoprotective agents such as bisphosphonates have been studied extensively and have been shown to inhibit cancer-related bone resorption in experimental and clinical studies. The third-generation bisphosphonate, ibandronate (BM 21.0955), is a potent compound for contro...

BACKGROUND Oral ibandronate is a single-nitrogen bisphosphonate whose efficacy is similar to that of IV ibandronate for the treatment of bone metastases. OBJECTIVE The aim of this study was to compare the cost-effectiveness of oral ibandronate with zoledronic acid and generic pamidronate (both administered by IV) for the treatment of bone metastases in patients with breast cancer receiving or...

This article will present what we know of the life and times of an important alchemist, Ibn Umayl. It is entitled ‘Towards a Context’ because I have not yet consulted a number of his treatises, which are mostly only available as manuscripts. Ibn Umayl’s position in alchemy accords with Hermetic doctrines, and may have developed as a traditionalist reaction to developments in alchemy around the ...

Centre de Référence de Médecine et de Réanimation Néonatale de l’Hôpital d’Enfants de Rabat, Centre Hospitalier Universitaire Ibn Sina, Avenue Ibn Rochd, Agdal, Rabat, Maroc, Unité Mixte de Recherche en Nutrition et Alimentation URAC 39, Université Ibn Tofail-CNESTEN, RDC-Nutrition AFRA/AIEA, Maroc, Equipe de Recherche en Santé et Nutrition du Couple Mère-Enfant, Faculté de Médecine et de Pharm...

PURPOSE The aromatase inhibitor anastrozole is a highly effective well-tolerated treatment for postmenopausal endocrine-responsive breast cancer. However, its use is associated with accelerated bone loss and an increase in fracture risk. The ARIBON trial is a double-blind, randomized, placebo-controlled study designed to evaluate the impact of bisphosphonate treatment on bone mineral density (B...

BACKGROUND Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE To confirm the 1 year results and provide more extensive safety and tolerability information for once-monthly dosing by a 2 year analysis. METH...

Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression. Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer. Ibandronate is a highly potent bisphosphonate available in both intravenous...

Oral daily and weekly bisphosphonates were considered, for several years, as the mainstay for the treatment of postmenopausal osteoporosis. However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long-term, hence outcomes. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedul...